NIOX Group (NIOX) H1 2024 earnings summary

Executive summary

• Revenue increased 12% year-over-year to £21.0 million, with strong growth in clinical and research sales and consistent growth in EBITDA and free cash flow.

• Adjusted EBITDA rose to £7.1 million, reflecting higher sales and a stable cost base.

• Cash generation remained robust, supporting a £4.2 million dividend and a new tender offer to return up to £21.0 million to shareholders.

• Expansion of distributor networks in the US and EMEA, and ongoing development of the next-generation NIOX Pro® device.

• Focused on building shareholder value through cash deployment for business needs and capital returns.

Financial highlights

• H1 2024 revenues increased 12% (15% constant currency) to £21.0m compared to H1 2023.

• Adjusted EBITDA: £7.1 million (H1 2023: £6.2 million), margin 33.8%.

• Profit before tax grew 52% to £4.4m (H1 2023: £2.9m).

• Cash at period end: £21.5 million, no debt.

• Operating profit: £4.2 million (H1 2023: £3.0 million).

Outlook and guidance

• Management and Board confident in achieving consensus market expectations for the full year.

• Trading in July and August slightly ahead of management expectations.

• Continued focus on organic growth and leadership in PoC FeNO testing.

• Ongoing strength of Sterling negatively impacts reported revenue, but minimal EBITDA effect.